Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases. Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit the growth of different types of malignancies. Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)is a kind of transmembrane glycoprotein, which is induced by epidermal growth factor (EGF) and develops inhibitory negative feedback by specific binding with epidermal growth factor receptor (EGFR). LRIG1 expression is broadly decreased in human cancer and breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival.
Molecular Weight:
85 kDa (predicted), 90-100 kDa (reducing condition, due to glycosylation)
TMPY-02264
* VAT and and shipping costs not included. Errors and price changes excepted
